Alpha memo: resveratrol exercise context boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Clarify that Receipt 1 is a feasibility/safety pilot and does not itself establish a 'no additive effect' efficacy finding; restate the alpha so the divergence is framed as one feasibility/physical-function trial vs. one negative cardiovascular-efficacy signal, rather than two opposite-direction efficacy results.
2. Acknowledge explicitly in the Caveats section that Receipt 2's excerpt is truncated and the magnitude/direction of the blunting cannot be fully verified from the bundle, even though the title is consistent with interference.
3. Tighten the title or sub-framing so it matches what the two receipts actually support: a context-dependent (population, dose, endpoint, duration) divergence rather than a confirmed additive-vs-blunting contrast.

Minor issues

• The 'Why this is surprising' section characterizes Receipt 1 as compatible with the additive hypothesis, but the pilot RCT excerpt describes feasibility/safety outcomes and physical function + mitochondrial measures — not a test of additive benefit. The memo should make clearer that Receipt 1 does not provide a positive efficacy signal, only feasibility; the 'split' is really one feasibility trial vs. one negative efficacy signal, not two opposite-direction efficacy signals.
• The alpha sentence says 'no additive effect on physical function to blunting cardiovascular gains,' but Receipt 1 does not report efficacy results in the excerpt; the memo should not phrase Receipt 1 as establishing a 'no additive effect' finding without that being supported by the cited receipt.
• Receipt 2 excerpt is truncated mid-sentence at 'Exercise training led to a 45', leaving the actual blunting magnitude unverified in-bundle; the memo should note this rather than implying the abstract fully describes the interaction.
• The 'combined receipts suggest' framing is appropriate hedging, but the title 'resveratrol exercise context boundary' could be tightened to signal that the memo is about a divergence between feasibility and efficacy signals, not a resolved boundary.

Reviewer note

The memo correctly identifies two relevant primary sources (the 2021 pilot RCT and the 2013 aged-men training study) and frames a bounded, falsifiable signal about context-dependent resveratrol–exercise interactions in older adults. Sources are recent, real, and directly cited via DOI. The main weakness is a mild overclaim in characterizing Receipt 1 as showing 'no additive effect on physical function' — the cited excerpt is a feasibility/safety pilot and does not report efficacy outcomes. Additionally, Receipt 2's excerpt is truncated, so the exact blunting magnitude should not be implied as fully verified from the bundle. The falsifier section is specific and well-constructed, and the limitations appropriately flag dose/duration/population confounding. With bounded edits to correct the Receipt 1 framing and acknowledge the truncated Receipt 2 excerpt, the memo would be accept-quality. Recommend revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis